公开(公告)号：US20250090632A1

公开(公告)日：2025-03-20

申请号：US18908031

申请日：2024-10-07

Applicant: Janssen Biotech, Inc.

Inventor： Omoniyi Adedokun ,  Daphane Chan ,  Yang Chen ,  Philippe Szapary

IPC: A61K38/17 ,  A61K39/00 ,  A61P1/00 ,  A61P37/06 ,  C07K16/24

Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.

公开(公告)号：US20240294625A1

公开(公告)日：2024-09-05

申请号：US18401874

申请日：2024-01-02

Applicant: Janssen Biotech, Inc.

Inventor： Omoniyi Adedokun ,  Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Christopher O'Brien ,  Kimberly Shields-Tuttle ,  Richard Strauss ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K39/3955 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04 ,  A61K2039/505 ,  C07K2317/565

Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240141032A1

公开(公告)日：2024-05-02

申请号：US17974956

申请日：2022-10-27

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Mobolaji Olurinde ,  Aparna Sahoo ,  Jacqueline Yee ,  Omoniyi Adedokun

IPC: C07K16/24 ,  A61P37/02

CPC classification number: C07K16/244 ,  A61P37/02 ,  A61K2039/505

Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial subcutaneous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20230151087A1

公开(公告)日：2023-05-18

申请号：US17986374

申请日：2022-11-14

Applicant: Janssen Biotech, Inc.

Inventor： Omoniyi Adedokun ,  Daphne Chan ,  Yang Chen ,  Philippe Szapary

IPC: C07K16/24 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61P37/06 ,  C07K2317/565 ,  A61K2039/545

Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequent subcutaneous doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20210308220A1

公开(公告)日：2021-10-07

申请号：US17212424

申请日：2021-03-25

Applicant: Janssen Biotech, Inc.

Inventor： Omoniyi Adedokun ,  Daphne Chan ,  Yang Chen ,  Philippe Szapary

IPC: A61K38/17 ,  C07K16/24 ,  A61P1/00 ,  A61P37/06

Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.

公开(公告)号：US20210171622A1

公开(公告)日：2021-06-10

申请号：US17174201

申请日：2021-02-11

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00 ,  A61P1/04 ,  A61K9/08 ,  A61K9/00

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.